Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00128908|
Recruitment Status : Terminated (Did not recruit)
First Posted : August 10, 2005
Last Update Posted : September 15, 2009
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Standard Continuous Highly Active Antiretroviral Therapy (HAART) Drug: Rapidly Cycled HAART||Phase 4|
Mathematical modeling has suggested that cyclic use of antiretroviral therapy can be an effective strategy in lowering viral load in HIV-1 infected patients when regular triple drug combinations have lost efficacy due to the emergence of HIV resistance mutations.
This is an open label, crossover pilot study to explore the safety and efficacy of a rapid cycling regimen of antiretroviral combination therapy in HIV-1 infected patients with virus harboring genotypic resistance to at least three classes of antiretroviral therapy.
The objectives are to study the feasibility, safety and efficacy of sequential combination therapy in HIV-1 infected patients with virus harboring genotypic resistance to at least three classes of antiretroviral agents and who currently have no adequate treatment options available.
This is an open-label, crossover, pilot study. Patients that fail their current regimen, and who currently have no adequate treatment options left, will be randomized to start either an alternating triple combination, or to start a continuous quadruple regimen of drugs. After 6 weeks, patients will crossover from either strategy to the other strategy for another 6 weeks. Each period is preceded by an interruption of all antiretroviral therapy for 4 weeks. In the study period when regimens are alternated, two combinations of three drugs with the least possible cross-resistance will alternate every week.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Sequential HAART in Treatment Resistant HIV-1 Infected Patients|
|Study Start Date :||September 2005|
|Actual Primary Completion Date :||January 2007|
|Actual Study Completion Date :||January 2007|
Active Comparator: Continuous triple-class therapy
Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
Drug: Standard Continuous Highly Active Antiretroviral Therapy (HAART)
Experimental: Alternating therapy
Patients will be assigned to weekly alternating dual-class regimen
Drug: Rapidly Cycled HAART
- Changes in plasma HIV-1 RNA load [ Time Frame: 12 weeks ]
- Changes in the genotype of the dominant quasispecies [ Time Frame: 12 weeks ]
- Replicative fitness of the dominant quasispecies [ Time Frame: 12 weeks ]
- Changes in CD4+ and CD8+ cell counts [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00128908
|HIV Outpatient Clinic, Academic Medical Center|
|Amsterdam, NH, Netherlands, 1105AZ|
|Study Chair:||Joep MA Lange, MD PhD||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|
|Study Director:||Ferdinand Wit, MD PhD||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|